VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Loibl, Sibylle; Jassem, Jacek; Sonnenblick, Amir; Parlier, Damien; Winer, Eric P.; Bergh, Jonas; Gelber, R.D.; Restuccia, Eleonora; Im, Y-H.; Huang, Chao-Yuan; Calvo, Isabel; Procter, Marion; Caballero, C.; Clark, Emma; Moreno, Henry L. Gomez; Bliss, Judith M.; Viale, Giovanna; Bines, José; Piccart, Martine

doi:10.1016/j.annonc.2022.06.009

Cited by 45 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This trial concluded that the addition of pertuzumab in the adjuvant setting may significantly improve invasive disease-free survival in patients with node-positive disease ( 43 ). However, no statistically significant difference was seen in OS after a median follow-up of 8.4 years ( 44 ).…”

Section: Adjuvant Therapy In the Context Of Neoadjuvant Strategy/acco...mentioning

confidence: 90%

Review of the status of neoadjuvant therapy in HER2-positive breast cancer

et al. 2023

View full text Add to dashboard Cite

PurposeThe development of human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of HER2-positive breast cancer. The aim of this article is to review the continually evolving treatment strategies in the neoadjuvant setting of HER2-positive breast cancer, as well as the current challenges and future perspectives.MethodsSearches were undertaken on PubMed and Clinicaltrials.gov for relevant publications and trials.FindingsThe current standard of care in high-risk HER2-positive breast cancer is to combine chemotherapy with dual anti-HER2 therapy, for a synergistic anti-tumor effect. We discuss the pivotal trials which led to the adoption of this approach, as well as the benefit of these neoadjuvant strategies for guiding appropriate adjuvant therapy. De-escalation strategies are currently being investigated to avoid over treatment, and aim to safely reduce chemotherapy, while optimizing HER2-targeted therapies. The development and validation of a reliable biomarker is essential to enable these de-escalation strategies and personalization of treatment. In addition, promising novel therapies are currently being explored to further improve outcomes in HER2-positive breast cancer.

show abstract

Section: Adjuvant Therapy In the Context Of Neoadjuvant Strategy/acco...mentioning

confidence: 90%

Review of the status of neoadjuvant therapy in HER2-positive breast cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Subgroup analysis by nodal status showed that patients with positive lymph node status in particular benefited from the therapy (HR = 0.77; 95% CI: 0.62 – 0.96), and patients with negative nodal status benefited less (HR = 1.13; 95% CI 0.68 – 1.86). The third interim analysis for overall survival has now been published, with a median follow-up of 8.4 years 22 . Just as in previous analyzes, the evaluation in terms of overall survival did not achieve statistical significance with an HR of 0.83 (95% CI: 0.68 – 1.02); however, the addition of pertuzumab did result in a numerical benefit.…”

Section: New Data On Patients With Her2-positive Breast Cancer Not Cl...mentioning

confidence: 99%

“…Nun wurde die 3. Interimsanalyse für das Gesamtüberleben mit 8,4 Jahren medianer Nachbeobachtungszeit vorgestellt 22 . Genauso wie bei den Voranalysen erreichte die Auswertung in Bezug auf das Gesamtüberleben keine statistische Signifikanz mit einer HR von 0,83 (95%-KI: 0,68 – 1,02), jedoch einen numerischen Vorteil für den zusätzlichen Einsatz von Pertuzumab.…”

Section: Neue Daten Bei Patientinnen Mit Her2-positivem Mammakarzinom...unclassified

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer

Fehm

Welslau

Müller

et al. 2023

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

show abstract

“…Interimsanalyse die 3. Interimsanalyse für das Gesamtüberleben mit 8,4 Jahren medianer Nachbeobachtungszeit vorgestellt worden 48 . Genauso wie bei den Voranalysen erreichte die Auswertung in Bezug auf das Gesamtüberleben keine statistische Signifikanz mit einer HR von 0,83 (95%-KI: 0,68 – 1,02), jedoch einen numerischen Vorteil für den zusätzlichen Einsatz von Pertuzumab.…”

Section: Anti-her2-therapien Im Neoadjuvanten Und Adjuvanten Settingunclassified

“…Subgroup analysis by nodal status showed that patients with positive lymph node status in particular benefited from therapy (HR = 0.77; 95% CI 0.62 – 0.96) and patients with negative nodal status benefited less (HR = 1.13; 95% CI 0.68 – 1.86). Now, after a second interim analysis, the third interim analysis for overall survival has been published with a median follow-up of 8.4 years 48 . Just as in previous analyses, the evaluation in terms of overall survival did not achieve statistical significance with an HR of 0.83 (95% CI: 0.68 – 1.02), but there was a numerical advantage for the addition of pertuzumab.…”

Section: Anti-her2 Therapies In the Neoadjuvant And Adjuvant Settingmentioning

confidence: 99%

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Fehm

Welslau

Müller

et al. 2022

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

show abstract

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Cited by 45 publications

References 0 publications

Review of the status of neoadjuvant therapy in HER2-positive breast cancer

Review of the status of neoadjuvant therapy in HER2-positive breast cancer

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Contact Info

Product

Resources

About